Figure 6. Mastoparan and Gemcitabine work synergistically in vivo.

4T1 mouse mammary carcinoma cells (1 × 10⁶ cells) were injected into the mammary fat pads of BALB/c mice. Mice were injected (IP) with saline, gemcitabine (60 mg/kg), Mastoparan (6 mg/kg). or a combination of gemcitabine and Mastoparan (60 and 6 mg/kg, respectively). Gemcitabine and Mastoparan treatment began 5 days post injection and continued Q7D and Q2D, respectively. (A) Tumour volume was recorded by caliper measurements every other day until the first mouse reached its humane endpoint At the end of the experiment, the mice were sacrificed, and the tumours were removed, weighed (B), and photographed (C). Data shown in A and B represent the average of 5 mice ± StDev (In panel A, StDev is only shown for saline and Gemcitabine + Mastoparan to illustrate variability in relevant treatment groups), and are significant (* denotes p < 0.05, in comparison to saline-treated mice) by Bonferroni multiple comparison test.